Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not
- PMID: 17192459
- DOI: 10.2337/db06-0565
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not
Abstract
Metabolic effects of the glucagon-like peptide-1 analog liraglutide and the dipeptidyl peptidase-IV inhibitor vildagliptin were compared in rats made obese by supplementary candy feeding. Female Sprague-Dawley rats were randomized to 12-week diets of chow or chow plus candy. The latter were randomized for 12 further weeks to continue their diet while receiving 0.2 mg/kg liraglutide twice daily subcutaneously, 10 mg/kg vildagliptin twice daily orally, or vehicle or to revert to chow-only diet. Energy expenditure was measured, and oral glucose tolerance tests (OGTTs) were performed. Body composition was determined by dual-energy X-ray absorptiometry scanning, and pancreatic beta-cell mass was determined by histology. Candy feeding increased weight, fat mass, and feeding-associated energy expenditure. Liraglutide or reversal to chow diet fully reversed weight and fat gains. Liraglutide was associated with decreased calorie intake and shifted food preference (increased chow/decreased candy consumption). Despite weight loss, liraglutide-treated rats did not decrease energy expenditure compared with candy-fed controls. Vildagliptin affected neither weight, food intake, nor energy expenditure. OGTTs, histology, and blood analyses indirectly suggested that both drugs increased insulin sensitivity. Liraglutide and vildagliptin inhibited obesity-associated increases in beta-cell mass. This was associated with weight and fat mass normalization with liraglutide, but not vildagliptin, where the ratio of beta-cell to body mass was low.
Similar articles
-
Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.Am J Physiol Endocrinol Metab. 2014 Nov 1;307(9):E830-7. doi: 10.1152/ajpendo.00370.2014. Epub 2014 Sep 16. Am J Physiol Endocrinol Metab. 2014. PMID: 25231186 Clinical Trial.
-
Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.Regul Pept. 2010 Feb 25;160(1-3):106-14. doi: 10.1016/j.regpep.2009.12.005. Epub 2009 Dec 30. Regul Pept. 2010. PMID: 20005262
-
Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.Diabetes. 2001 Nov;50(11):2530-9. doi: 10.2337/diabetes.50.11.2530. Diabetes. 2001. PMID: 11679431
-
How do different GLP-1 mimetics differ in their actions?Curr Diab Rep. 2006 Nov;6(5):365-72. doi: 10.1007/s11892-006-0007-x. Curr Diab Rep. 2006. PMID: 17076997 Review.
-
[Incretin related agents for treatment of diabetes mellitus].Nihon Naika Gakkai Zasshi. 2009 Apr 10;98(4):809-16. doi: 10.2169/naika.98.809. Nihon Naika Gakkai Zasshi. 2009. PMID: 19472544 Review. Japanese. No abstract available.
Cited by
-
Dipeptidyl-peptidase 4 (DPP4) mediates fatty acid uptake inhibition by glucose via TAS1R3 and GLUT-2 in Caco-2 enterocytes.Heliyon. 2024 Apr 25;10(9):e30329. doi: 10.1016/j.heliyon.2024.e30329. eCollection 2024 May 15. Heliyon. 2024. PMID: 38707340 Free PMC article.
-
Development of Syringaldehyde as an Agonist of the GLP-1 Receptor to Alleviate Diabetic Disorders in Animal Models.Pharmaceuticals (Basel). 2024 Apr 22;17(4):538. doi: 10.3390/ph17040538. Pharmaceuticals (Basel). 2024. PMID: 38675498 Free PMC article.
-
The Role of Probiotics in Managing Glucose Homeostasis in Adults with Prediabetes: A Systematic Review and Meta-Analysis.J Diabetes Res. 2024 Mar 18;2024:5996218. doi: 10.1155/2024/5996218. eCollection 2024. J Diabetes Res. 2024. PMID: 38529045 Free PMC article. Review.
-
Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice.Endocrine. 2024 Jul;85(1):222-232. doi: 10.1007/s12020-024-03734-2. Epub 2024 Feb 20. Endocrine. 2024. PMID: 38378894
-
Management of Hypertension in Diabetic Kidney Disease.J Clin Med. 2023 Oct 31;12(21):6868. doi: 10.3390/jcm12216868. J Clin Med. 2023. PMID: 37959333 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical